33 research outputs found

    Green Production of Anionic Surfactant Obtained from Pea Protein

    Get PDF
    A pea protein isolate was hydrolyzed by a double enzyme treatment method in order to obtain short peptide sequences used as raw materials to produce lipopeptides-based surfactants. Pea protein hydrolysates were prepared using the combination of Alcalase and Flavourzyme. The influence of the process variables was studied to optimize the proteolytic degradation to high degrees of hydrolysis. The average peptide chain lengths were obtained at 3–5 amino acid units after a hydrolysis of 30 min with the mixture of enzymes. Then, N-acylation in water, in presence of acid chloride (C12 and C16), carried out with a conversion rate of amine functions of 90%, allowed to obtain anionic surfactant mixtures (lipopeptides and sodium fatty acids). These two steps were performed in water, in continuous and did not generate any waste. This process was therefore in line with green chemistry principles. The surface activities (CMC, foaming and emulsifying properties) of these mixtures were also studied. These formulations obtained from natural renewable resources and the reactions done under environmental respect, could replace petrochemical based surfactants for some applications

    Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

    Get PDF
    Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

    Réglementation douanière et fiscale de la filière porcine aux Caraïbes

    Full text link
    Cette étude est une présentation de la réglementation douanière et fiscale de la filière porcine aux Caraïbes et en particulier au niveau : - des DOM français : Guadeloupe et Martinique, - de deux états du Commonwealth : Dominique et Sainte Lucie. Dans ces îles, les produits des secteurs de la viande et des intrants d'élevage de la filière porcine sont passibles de taxes. Dans les DOM, on distingue trois types de taxes : - les droits de douanes : taxe communautaire dont la valeur varie selon le produit et le pays d'origine, - la TVA : taxe nationale de 2,10 % du prix HT pour les produits agricoles, - l'OM et le DAOM : taxes spécifiques appliquées à tous les produits introduits dans les DOM. La Dominique et Sainte Lucie possèdent aussi trois taxes : - taxe d'importation, - taxe de consommation, - taxe à la vente. Le taux de ces taxes et leurs modes d'application diffèrent selon les îles. A titre d'exemple, les taxes appliquées sur les produits du secteur de la viande originaires de la métropole et introduits en Guadeloupe, représentent 11,1 % du prix CAF (droits de douanes nuls). A la Dominique l'importation de ces produits est passible de taxes allant de 31,2 % à 62,5 % du prix CAF selon la catégorie de la viande (résumé d'auteur

    Enhanced light coupling in sub-wavelength single-mode silicon on insulator waveguides

    No full text
    We report on NIR efficient end-coupling in single-mode silicon on insulator waveguides. Efficient coupling has been achieved using Polymer-Tipped Optical Fibers (PTOF) of adaptable radius of curvature (ROC). When compared with commercial micro lenses, systematic studies as a function of PTOF ROC, lead for subwavelength PTOF to a coupling factor enhancement as high as 2.5. This experimental behavior is clearly corroborated by radial FDTD simulations and an absolute coupling efficiency of about 50% is also estimated
    corecore